Comparative effectiveness research in first-line therapies for untreated multiple myeloma

未经治疗的多发性骨髓瘤一线疗法的比较有效性研究

• 批准号: 23791092
• 负责人: TERASAWA Teruhiko
• 金额: $ 2.75万
• 依托单位: Fujita Health University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23791092/
• 关键词: 血液腫瘍学; 多発性骨髄腫; 比較効果研究; メタアナリシス; 国際情報交換; 国際情報交流、米国

Currently available first-line therapies for untreated multiple myeloma consist of conventional chemotherapies, high-dose chemotherapies followed by autologous stem-cell transplantation, and novel agents-based therapies, which are selected on the basis of important clinical factors such as age, and biochemical, cytogenetic, and molecular markers. We performed systematic reviews and meta-analyses to evaluate comparative efficacy of these therapeutic strategies, and critically appraised the evidence on the prognostic factors.

目前可用于未经治疗的多发性骨髓瘤的一线治疗包括常规化疗、高剂量化疗后自体干细胞移植和基于新药的治疗，这些治疗是根据重要的临床因素（如年龄、生化、细胞遗传学和分子标志物）选择的。我们进行了系统回顾和荟萃分析，以评估这些治疗策略的比较疗效，并严格评估预后因素的证据。